Silo Pharma, Inc.

NASDAQ:SILO

$0.9496 USD

$0.01 (1.02%)

Volume
73.2K
Average Volume
269.63K
Market Capitalization
$4.26M
P/E Ratio
-1.08
Dividend Yield
0.00%
Price Target
$
Year High
$4.50
Year Low
$0.77
Payout Ratio
$0.00
Current Ratio
$7.91

Industry, Sector & symbol

Stock Exchange NASDAQ Capital Market
CEO Mr. Eric Weisblum
Industry Biotechnology
Sector Healthcare
Current Symbol SILO
CUSIP 82711P102
CIK 0001514183
Web https://silopharma.com
Phone 718 400 9031
Currency USD
Employees 3
Country US

Liquidity

Debt-to-Equity Ratio 0.00
Payout Ratio 0.00
Current Ratio 7.91
Quick Ratio 7.91
Cash Ratio 4.65

Sales & Book Value

Annual Sales $72102
Price / Sales 59.06
Cash Flow -0.89
Price / Cash Flow -1.11
Price / Book 0.60

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Sell
Rating Score(0-5) 2
Research Coverage 0 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-1.2
Trailing P/E Ratio -1.08
PEG Ratio 1.28
P/E Growth 1.28
Net Income $-3.7M
Net Margin -5247.34%
Pretax Margin -5150.81%
Return on Equity -62.51%
Return on Assets -44.16%

Financials Score

AltmanZ Score -1.26
Piotroski Score 1.00
Working Capital 7.22M
Total Assets 8.57M
Ebit -3.88M
Market Cap 4.26M
Total Liabilities 1.78M

Poll Results

About Silo Pharma, Inc. (NASDAQ:SILO) Stock

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple s ... clerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

2024-11-29 08:05:00

Prototype development and feasibility testing underway for optimized subcutaneous delivery SARASOTA, FL, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a collaboration agreement with Kymanox for specialized design and development of a subcutaneous insertion device for SP-26, the Company's ketamine-loaded implant therapeutic targeting fibromyalgia and chronic pain. Under terms of the agreement, Kymanox will conduct an initial proof-of-concept design phase followed by full system prototype and feasibility testing to determine optimal insertion depth in tissue.

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

2024-11-18 08:40:00

Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

2024-10-31 08:35:00

The implant demonstrates stability and consistent drug release, supporting further analytical testing and development SARASOTA, FL, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced promising results from recent sterilization and dissolution tests of its SP-26 ketamine-loaded implant for fibromyalgia and chronic pain. These tests were conducted under the Company's current development agreement with Sever Pharma Solutions.

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

2024-09-10 06:35:00

Proposal submitted for FDA 505(b)(2) regulatory pathway for SPC-15 approval Advancing path to IND submission for first-in-human trials SARASOTA, FL, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD) and stress-induced anxiety disorder.

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

2024-08-14 14:30:00

SP-26 dissolvable ketamine-based injectable implant targets chronic pain and fibromyalgia Sever Pharma to scale-up extrusion processes and continue analytical testing for novel non-opioid treatment SARASOTA, FL, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a new agreement with Sever Pharma Solutions for scale-up extrusion of the Company's SP-26 ketamine-loaded implant therapeutic targeting fibromyalgia and chronic pain. In addition, Sever Pharma Solutions will continue with analytical testing of the ketamine hydrochloride (ketamine HCL) polymer implants using the optimal time-released, dose-controlled formulation previously selected by Silo for continuing pre-clinical studies.

Frequently Asked Questions

What is the current Silo Pharma, Inc. (SILO) stock price?

Silo Pharma, Inc.(NASDAQ:SILO) stock price is $0.9496 in the last trading session. During the trading session, SILO stock reached the peak price of $4.5 while $0.77 was the lowest point it dropped to. The percentage change in SILO stock occurred in the recent session was 1.02% while the dollar amount for the price change in SILO stock was $0.01.

SILO's industry and sector of operation?

The NASDAQ listed SILO is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of SILO?

Mr. Daniel E. Ryweck | Chief Financial Officer
Mr. Eric Weisblum | Chairman, President & Chief Executive Officer
|
|
|

How many employees does SILO have?

Number of SILO employees currently stands at 3. SILO operates from 677 N. Washington Boulevard, Sarasota, FL 34236, US.

Link for SILO official website?

Official Website of SILO is: https://silopharma.com

How do I contact SILO?

SILO could be contacted at phone #718 400 9031 and can also be accessed through its website. SILO operates from 677 N. Washington Boulevard, Sarasota, FL 34236, US.

How many shares of SILO are traded daily?

The average number of SILO shares traded daily for last 3 months was 269.63K.

What is the market cap of SILO currently?

The market value of SILO currently stands at $4.26M with its latest stock price at $0.9496